Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897091 · ClinicalTrials.gov registry record
S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 750
- Enrollment target
NCT00897091 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 750 participants.
The verdict
NCT00897091 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in predicting outcome in postmenopausal women with hormone receptor-positive, node-positive breast cancer treated with tamoxifen with or without cyclophosphamide, doxorubicin, and fluorouracil.
Interventions
- GENETIC microarray analysis
- OTHER diagnostic laboratory biomarker analysis
- GENETIC reverse transcriptase-polymerase chain reaction
- GENETIC comparative genomic hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897091
The ClinicalTrials.gov registry entry for NCT00897091 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which microarray analysis is the first listed.
NCT00897091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00897091 about?
NCT00897091 is a clinical study titled "S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is l...
What is the current status of trial NCT00897091?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2006-07. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00897091?
The interventions under investigation include: microarray analysis (GENETIC), diagnostic laboratory biomarker analysis (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC), comparative genomic hybridization (GENETIC).
Who is sponsoring clinical trial NCT00897091?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.